HC Wainwright Issues Positive Forecast for DWTX Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Stock analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Dogwood Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of ($0.30) for the quarter, up from their previous estimate of ($0.49). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.62) EPS, FY2028 earnings at ($1.71) EPS and FY2029 earnings at $0.72 EPS.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Wall Street Zen lowered Dogwood Therapeutics to a “strong sell” rating in a research report on Saturday, December 13th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Trading Up 10.7%

Shares of DWTX opened at $3.00 on Monday. The company has a market capitalization of $100.21 million, a price-to-earnings ratio of -0.16 and a beta of 1.90. The stock has a 50 day moving average of $2.95 and a 200 day moving average of $4.66. Dogwood Therapeutics has a 12 month low of $2.60 and a 12 month high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Wednesday, March 18th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.96.

Institutional Investors Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the SEC. Institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.